Introduction
============

Pulmonary hypertension (PH) refers to a complex group of cardiopulmonary diseases that may lead to right-sided heart failure and reduced life expectancy ([@B67]). Pulmonary arterial hypertension (PAH) represents group 1 within the PH classification system ([@B179]). PAH is characterized by precapillary PH (i.e., mean pulmonary arterial pressure ≥ 25 mmHg and normal pulmonary capillary wedge pressure ≤ 15 mmHg), as a consequence of exacerbated remodeling and hypertrophy of the walls of the pulmonary arteries (PAs) ([@B67]). The most severe form of PH, PAH has a prevalence of 15 cases per million adult population, incidence of 2.4 cases per million adult population per year ([@B132]), and mean survival rate of 2.8 years in the absence of specific treatments ([@B132]; [@B179]).

Current knowledge on PAH pathophysiology highlights microenvironmental changes in the pulmonary vessels as the initial cause of the disease. Crosstalk among endothelial cells (ECs), pulmonary arterial smooth muscle cells (PASMCs), myofibroblasts, pericytes, and circulating immunologic cells triggers PAH pathogenesis ([@B74]). Elevated pulmonary vascular resistance (PVR) causes insult to the right ventricular (RV) myocardium, with subsequent activation of neurohormonal, immunological, and mechanical-stretch signaling ([@B205]). The poor prognosis of PAH is mainly a consequence of long-term pressure overload in the RV chamber, which initially responds with adaptive myocardial hypertrophy. This response is followed by progressive contractile dysfunction, global heart failure, and premature death ([@B205]; [@B189]).

Treatment of patients with PAH is palliative. Available agents include lung vasodilators, such as phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, prostacyclin analogs, and guanylyl cyclase stimulators ([@B67]). Lung transplantation is an important strategy in eligible subjects with advanced PAH who are refractory to drug intervention ([@B67]). Current treatments of PAH simply control the intense PA vasoconstriction, but recent advances in understanding disease pathophysiology have driven efforts to develop new pharmacological strategies targeting the irreversible remodeling of the pulmonary vascular bed. Favorable actions in the hypertrophied and dysfunctional RV are required for better outcomes, and there is a clear need for pleiotropic targets with beneficial roles throughout the cardiopulmonary system (pulmonary vessel and cardiac cells).

Adenosine has a well-known pulmonary vasodilator effect with a rapid onset of action ([@B167]; [@B150]). Adenosine use is recommended as an alternative strategy in pulmonary vasoreactivity testing for identification of patients suitable for high-dose calcium channel blocker treatment ([@B67]). Patients suffering from PAH exhibit low adenosine levels in the pulmonary circulation, suggesting that this nucleoside plays a role in PAH pathophysiology. The reduction of the adenosine release on pulmonary vascular endothelium is consequent to the endothelial dysfunction that is present in PAH. Low levels in PAH may also be explained by increased activity of the adenosine deaminase in the pulmonary circulation ([@B170]), which was found in rats with hemolysis-associated pulmonary hypertension ([@B195]). However, clinical implications of the adenosine deaminase or its inhibitors in PAH remain unclear. Adenosine promotes various beneficial effects in the heart ([@B177]) and has been defined as a retaliatory metabolic product ([@B149]).

Long-term use of adenosine in PAH and RV failure has been limited by its extremely short half-life ([@B150]) and adverse effects by non-selective activation of its four receptor subtypes. Nevertheless, adenosine receptors (ARs) promote multiple salutary actions in cardiac and vascular cells, including ECs, fibroblasts, and myocytes ([@B133]; [@B85]). Immune cells express ARs to respond to the modulatory effects of adenosine in an inflammatory environment ([@B83]). Researchers from several fields are considering the possibility of targeting ARs as a therapeutic approach in various clinical conditions, including cerebral and cardiac diseases, sleep disorders, immune and inflammatory disorders, and cancer ([@B98]; [@B83]; [@B133]; [@B22]; [@B85]).

This review compiles findings on the specific roles of each AR subtype in the cardiovascular system. The work focuses on AR activities in the small circulation, specifically in PAH pathogenesis, including the aberrant cellular proliferation and influx of inflammatory cells in and around various components of the vascular wall, as well as the distinct roles of ARs in RV cells. The main goal of this review is to answer an intriguing question: Does a specific AR exist that could be considered as a future target with pleiotropic potential in the whole cardiopulmonary system of patients with PAH?

Pulmonary Vascular Changes in PAH
=================================

Before addressing the potential benefits of targeting specific ARs for the treatment of PAH, we must understand the intrinsic pathophysiological mechanisms of this disease. Dynamic interactions among cells in the pulmonary vascular bed are the main determinant of cellular behavior (e.g., proliferation, apoptosis, differentiation, migration, and survival) in PA walls. Abnormal cell communication can lead to development of PAH ([@B46]; [@B213]; [@B73]; [@B74]). Crosstalk between PA cells is regulated through direct cell--cell contact and release of bioactive factors, such as EC-produced paracrine factors that influence the proliferation of PASMCs and fibroblasts ([@B46]; [@B171]; [@B4]).

Below a cross-sectional diameter of 500 μm (lobular to intra-acinar level), the medial layer of the PAs is typically composed solely of smooth muscle cells (SMCs), due to loss of elastic fibers. Beyond this level, the PAs leave their adjacent airways and become barely muscularized precapillary arterioles ([@B73]). Vascular remodeling in the lungs of PAH patients initially begins in this type of arteriole and presents as PASMC hyperproliferation, underlining the importance of this cell type in PAH pathogenesis ([@B175]; [@B73]). Early lesions correspond to hypertrophic and hyperplastic PASMCs within the tunica media ([@B73]). The abnormal proliferation of PASMCs during PAH development occurs in response to the signaling of growth factors, including potent mitogens and chemoattractants for vascular cells, which bind to and activate surface tyrosine kinase receptors (TKRs) ([@B175]).

Pulmonary ECs play a crucial role during the formation and maturation of blood vessels, producing and releasing growth factors that recruit and stabilize all vascular cells ([@B60]; [@B80]). [@B46] showed that EC-induced PASMC growth was greater in tissues from PAH patients than from controls. Dysregulation of this process and excessive release of growth factors by ECs are intrinsic abnormalities linked to PAH pathogenesis. Indeed, abnormal communication between ECs and other vascular cells in PAH may occur due to loss-of-function of the endothelium.

Among different factors, bone morphogenic protein (BMP) signaling regulates pulmonary EC survival and differentiation ([@B193]). Patients with PAH show abnormal BMP signaling, linked to mutations of bone morphogenetic protein receptor-2 (BMPR2) in ECs ([@B193]). These mutations could lead to deleterious consequences in ECs and PASMCs. Loss of BMPR2 signaling in ECs may increase apoptosis in response to environmental stress and injury, particularly at the level of the distal PAs ([@B193]). This apoptosis could be an initiating mechanism for PAH by leading to vessel obliteration due to degeneration of EC structures ([@B217]). Excessive loss of ECs promotes the development of apoptosis-resistant and hyperproliferative ECs, which are characteristic features of later stages of PAH ([@B204]).

The initial trigger for pulmonary EC injury is unknown, although some events, such as shear stress, local inflammation, genetic predisposition, toxins, and reactive oxygen species (ROS)-induced cell damage, might be important inducers of endothelial dysfunction ([@B4]). Exuberant proliferation of ECs leads to formation of plexiform lesions. These dynamic networks of vascular channels formed by the monoclonal proliferation of ECs ([@B184]) are a morphologic hallmark of severe PAH. A single plexiform lesion can occlude the entire length of an affected vessel ([@B26]). However, debate surrounds the functional importance of these lesions in the context of PAH, as it remains unclear if they have a role in disease progression or are simply a morphologic indicator of irreversible, end-stage disease ([@B197]; [@B1]; [@B101]; [@B184]).

In PASMCs, signaling by BMPR2 is necessary for the control of cell proliferation and differentiation ([@B199]; [@B68]). Together with EC-induced cell proliferation and medial hypertrophy, BMPR2 mutations in PASMCs participate in the process of initiating or maintaining pulmonary vessel hypertrophy in PAH patients ([@B216]).

Fibroblasts play important roles in PAH pathogenesis by responding to injury and chemoattraction via endothelium-derived growth factors. Rapid migration of fibroblasts to the injured vessel leads to formation of the neointimal layer and, most importantly, fibroblast transdifferentiation into other cell types, including myofibroblasts -- an abnormal type of PASMC that contributes to muscularization of the distal vessels ([@B172]; [@B181]; [@B171]).

Taken together, these findings indicate that any effect on BMPR2 signaling may trigger abnormal communication between ECs, PASMCs, and fibroblasts via growth factors. Subsequently, these growth factors trigger hyperproliferation and differentiation of cells, formation of plexiform lesions, obliteration and fibrosis of the vessels, and increases of PVR and pulmonary vascular pressure.

In an elegant review, [@B175] summarized the growth factors that are most clearly implicated in PAH pathogenesis. The review showed increased signaling of the following molecules in injured pulmonary vascular cells: vascular endothelial growth factor (VEGF), transforming growth factor alpha and beta (TGF-α and TGF-β), platelet-derived growth factor (PDGF), and hepatocyte growth factor (HGF) ([@B175]). All of these growth factors bind to TKRs, resulting in multi-phosphorylation of tyrosine residues for the assembly of downstream signaling molecules that are recruited to the receptor and activated in response to agonist stimulation ([@B122]). Subsets of intracellular signaling components influenced by growth factor receptor activation are intertwined in a complex network. Examples of intracellular molecules activated by TKRs are phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt), mitogen-activated protein kinases (Ras/Raf/MAPK/ERK), protein kinase C (PKC), Janus kinase (JAK), signal transducer and activator of transcription (STAT), and cyclins (a family of proteins that control cell cycle progression by activating cyclin-dependent kinases) ([@B114]; [@B122]).

Roles of TKRs and their antagonists in PAH have been reviewed, and cardiac safety issues of these molecules have been raised, especially in patients with heart disease that is intrinsically related to pulmonary vascular disease ([@B72]). The large blockage spectrum and lack of selectivity of TKR antagonists would provide unexpected toxicities, including injury to the pulmonary vasculature. Furthermore, the benefit-to-risk ratio of available TKR antagonists is low in the context of PAH ([@B72]). Thus, new approaches for PAH treatment should be aimed at ensuring a low toxicity profile, in addition to the high anti-proliferative efficacy.

Accumulating evidence shows that RhoA, a member of the Ras homolog gene family, and its downstream effectors, the Rho kinases (ROCKs), mediate the pathogenesis of PAH through their pro-proliferative contributions ([@B146]; [@B75]; [@B25]). ROCK downregulates expression of anti-proliferative molecules, leading to acceleration of cell cycle progression and vascular cell hyperproliferation ([@B118]; [@B174]). Distal muscularization of pulmonary vessels has been linked to amplification of the RhoA/ROCK pathway in PASMCs ([@B49]; [@B51]; [@B10]; [@B107]).

Another important factor involved in endothelium-smooth muscle interactions, serotonin makes a major contribution to PASMC hyperplasia in PAH ([@B46]). Serotonin-mediated PASMC proliferation was greater in mice with genetically mutated BMPR2 ([@B128]). The BMP and serotonin mechanisms are convergent in PASMCs; both stimulate RhoA/ROCK signaling downstream for a pro-proliferative phenotype ([@B127]). These previous reports suggest that vascular cell proliferation induced by downstream growth factors could be attenuated, in part, through inhibition of RhoA/ROCK signaling.

The RhoA/ROCK pathway is of interest to pharmaceutical companies due to the pleiotropic effects of its inhibitors in numerous diseases ([@B52]). Fasudil is a ROCK inhibitor that has shown salutary effects in the cardiopulmonary system of PAH patients and in different experimental models of the disease. These effects derive from its anti-proliferative profile in the pulmonary vessels, which it achieves by reducing PVR and RV overload ([@B142]; [@B163]; [@B66]; [@B99]; [@B209]; [@B76]). Nevertheless, the cardioprotective potential of this pharmacological modality is not completely clear, as the effect of fasudil on reducing PAH-related changes in the RV may be an indirect response of the lower afterload in the right heart chamber. In addition to the beneficial effects of ROCK inhibitors in the left heart ([@B35]; [@B191]), their direct effects should be investigated in the RV cells, because the structures, hemodynamics, and functions of both ventricles are distinct.

Secondarily to the pro-proliferative phenotype in pulmonary vascular cells, damaged crosstalk between ECs and PASMCs can exacerbate PA vasoconstriction as a consequence of an imbalance in the production of endothelium-derived vasodilator \[nitric oxide (NO) and prostacyclin\] and constrictor factors (endothelin-1, serotonin, and angiotensin II). Crosstalk dysfunction is a pivotal element in the development and progression of the disease ([@B74]).

Furthermore, PAH is among many pathophysiologic conditions that are linked to inflammation ([@B175]). Inflammation has a pivotal role during development of PAH in humans and in animal models of the disease. Some patients with PAH present increased levels of tumor necrosis factor alpha (TNF-α), interleukins 12 and 6 (IL-12 and IL-6), and interferon-γ, associated with other inflammatory signals, such as plasma cell dyscrasia polyneuropathy. Induction of PAH in rodents by chronic hypoxia or monocrotaline leads to an increase in the number of inflammatory cells in the lungs ([@B138]; [@B182]; [@B16]). Vascular and inflammatory cells are important local sources of cytokines and chemokines, which can trigger pulmonary vascular remodeling in PAH ([@B188]; [@B162]). Histopathological studies have demonstrated the presence of complement system components, autoantibodies, and inflammatory cells (neutrophils) in the vessel lumen, which can bind to the endothelium and may infiltrate the medial muscular layer. Inflammatory infiltrate in the neointimal layer is composed of T- and B-lymphocytes, with macrophages, mast cells, and dendritic cells present in the adventitial layer. Lymphoid follicles, characterized by T cells, B cells, and plasmacytoid dendritic cells (APCs), are found in the periadventitial space ([@B186]; [@B162]). Thus, reversion of the pulmonary vessel injury in PAH requires an anti-inflammatory profile.

Cardiovascular Functions of Adenosine and its Receptors
=======================================================

Adenosine is a purine nucleoside that is widely distributed in all tissues. Structurally, adenosine is formed by the linking of adenine to a ribose sugar molecule. Synthesis of adenosine is increased after myocardial infarction (MI) ([@B32]; [@B82]; [@B9]; [@B92]). Adenosine is synthesized inside and outside the cells for immediate use and is not stored in vesicles for future release. For these reasons, this molecule is an autacoid, similar to several biological transmitters ([@B148]; [@B36]; [@B37]; [@B34]; [@B219]).

Extracellular production of adenosine depends on a cascade reaction initiated by ATP and ADP as substrates ([@B45]). ATP and ADP are converted to AMP by catalysis of ectonucleoside triphosphate diphosphohydrolases (NTPDases 1, 2, 3, and 8) on the cell surface, followed by AMP hydrolysis to adenosine by ecto-5′-nucleotidase (NTE5/CD73) ([@B12]; [@B87]; [@B34]; [@B11]; [@B77]). Intracellular adenosine might be provided through other signaling processes. One of these events is the catabolism of ATP from stressed cells under hypoxia ([@B78]). This condition might be responsible for the perturbed recycling of adenosine and ATP, and the increased activity of specific phosphatases leads to excessive levels of adenosine ([@B183]). Another source of intracellular adenosine is the cytosolic 5′-nucleotidase-mediated metabolism (dephosphorylation) of AMP, which is formed from the degradation of cyclic AMP (cAMP) by phosphodiesterases. Intracellular adenosine is also importantly generated by the conversion of *S*-adenosylhomocysteine to adenosine and homocysteine, catalyzed by *S*-adenosylhomocysteine hydrolase ([@B112]; [@B88]; [@B5]).

Adenosine is converted, extra- or intracellularly, to inosine by adenosine deaminase ([@B61]; [@B180]; [@B7]). Phosphorylation of adenosine to AMP by adenosine kinase reduces the intracellular concentration of adenosine ([@B33]; [@B40]; [@B152]; [@B18]). The adenosine concentration depends on two families of transmembrane proteins, concentrative and equilibrative nucleoside transporters, which facilitate the movement of nucleosides, nucleobases, and their analogs across the cell membrane. There are four isoforms of human equilibrative nucleoside transporters, but only ENT1 and ENT2 are expressed in tissues throughout the body ([@B110]; [@B156]). The adenosine transport process usually follows gradients from high to low concentration, with no energy spending ([@B22]). The extracellular adenosine concentration varies substantially between tissue types ([@B165]). The local adenosine concentration may be increased from the nano- to the micromolar range, signaling tissue injury, by extreme pathophysiological cell activation (seizure) or insults due to ischemia, trauma, inflammation, or cancer ([@B64]; [@B125]; [@B58]; [@B83]; [@B7], [@B6]; [@B81]).

[@B41] described adenosine as a potent vasodilator-like molecule. In the cardiovascular system, adenosine offers protective effects against episodes of angina pectoris, preconditioning, and ischemia/reperfusion (I/R) injury ([@B151]; [@B117]; [@B208]; [@B139]). Adenosine mediates its physiological effects on tissue regeneration and repair by binding to and activating a family of G-protein coupled receptors, denoted P1 purinoceptors and adenosine receptors A~1~, A~2A~, A~2B~, and A~3~ ([@B164]; [@B135]), all expressed in the cardiovascular system ([@B85]).

The transduction pathways involved in adenosine signaling through its receptors in the cardiovascular system are complex. A~1~ receptor may couple to different G-proteins in order to regulate adenylyl cyclase (AC), phospholipase C (PLC), Ca^2+^ and K^+^ channel functions, and possesses a high affinity for adenosine ([@B63]). When it is coupled to Gi protein it inhibits AC and modulates K^+^ and Ca^2+^ channels activities. But it may also couple with Gs to activate AC, or with Gq/11 to stimulate PLC enzyme and, subsequently, the inositol triphosphate (IP~3~) and diacylglycerol (DAG) production ([@B85]). It was also described that A~1~ receptor promotes K^+^ efflux via βγ subunit of G-protein inwardly rectifying channels (GIRK/K~IR~3) ([@B116]; [@B111]; [@B15]; [@B143]).

The A~2A~ receptor is very sensitive to adenosine ([@B63]). This receptor couples with Gs to activate AC and increase cAMP levels in the cardiovascular system and it interacts with A~1~ receptor, dopamine D~2~, metabotropic glutamate 5, NMDA and cannabinoid CB~1~ receptor in other organs, but the specific functions and occurrence of such interactions remains unknown ([@B85]).

Adenosine has the lowest affinity for the A~2B~ receptor subtype ([@B63]). A~2B~ signaling is mediated via Gs protein to stimulate AC activity, but it also may couple to Gq/11 protein to activate PLC ([@B85]). It was reported that A~2B~ receptor might also modulate the arachidonic acid cascade ([@B39]). Additionally, A~2B~ signaling can increase endothelial NO bioavailability with subsequent K~ATP~ channel opening in rodent vascular cells ([@B141]; [@B90]). A~2B~ may also couple to p38-MAPK in coronary vessels ([@B194]).

The A~3~ receptor is the newest subtype that was identified ([@B63]). Similarly to A~1~ receptor, it can couple to Gi protein to inhibit AC activity, and also to Gq/11 to modulate PLC and Ca^2+^ intracellular handling ([@B85]). Involvement of A~2A~ and A~2B~ receptor-mediated vasodilation has been reported in several vessels, including the muscular arteries \[mesenteric ([@B89]), renal ([@B168]), and coronary arteries ([@B59])\] and elastic arteries, including the aorta of several species \[guinea pigs ([@B187]), rats ([@B159]), and hamsters ([@B160])\]. Adenosine relaxes precontracted isolated PA rings, an effect that probably occur via A~2A~ and A~2B~ receptor activation ([@B47]). Some investigators have suggested that vascular relaxation in response to A~2A~ activation may be independent of ECs ([@B153]), whereas others have shown substantial EC involvement ([@B130]). Resolving this controversy, researchers demonstrated that A~2A~ is located in both the vascular endothelium and vascular SMCs ([@B119]), and that its activation is involved in vasodilation ([@B123]; [@B159]).

Activation of the Gs protein-coupled endothelial A~2A~ receptor triggers NO release by activating the AC-protein kinase A (PKA) pathway ([@B94]; [@B166]). Activation of A~2A~ in vascular SMCs increases formation of cAMP and activation of PKA, which leads to phosphorylation and opening of potassium channels. This effect, in turn, causes hyperpolarization and vasodilatation ([@B113]). In contrast, the A~1~ and A~3~ receptors negatively modulate A~2A-B~ receptor-induced vasodilation ([@B192]; [@B145]; [@B158]). The A~1~ receptor plays a negative role in regulating blood pressure, causes contraction of vascular smooth muscle, and decreases coronary blood flow ([@B158]). These findings indicate that adenosine can act as a vasoconstrictor or a vasodilator, depending on its interaction with specific receptor subtypes, plasma levels, and tissue localization. Differences in the adenosine regulation of the pulmonary vascular tonus might be explained, in part, due to the higher affinity of this nucleoside for the A~1~ receptor (promotes pulmonary vasoconstriction) than for A~2B~ receptor (promotes pulmonary vasodilation). [@B170] have described a correlation of the progression of PH and the lower level of adenosine observed in patients. Low adenosine levels in lungs from PH patients are likely to stimulate A~1~ more than A~2B~ receptors, thus contributing to the vasoconstriction in those subjects.

The pulmonary circulation is one of the few regions in the body where activation of ARs has a dual function (i.e., promoting both contraction and relaxation) that depends on the basal tone of the blood vessel ([@B23]). In pulmonary vessels, A~1~ receptors are stimulated under circumstances of low vasculature tone, thereby promoting vasoconstriction; when vessel tone is high, A~2~ receptor subtypes are activated and promote vasodilation ([@B190]). We can extrapolate these findings to the context of PAH. In terms of the induction of pulmonary vessel relaxation, ARs in the large PAs (vs. small arteries) were reported to be the A~2B~ subtype (vs. A~2A~ subtype) ([@B190]). This information is relevant in the pathological environment of PAH, as the disease begins in the distal microvasculature. Thus, we may assume that activation of A~2~ receptor subtypes in the pulmonary vessels could be targeted to reduce the extremely high vascular tone in PAH patients.

Pharmacological manipulation of adenosine signaling is of great interest for numerous cardiovascular conditions. Several potential agonists or antagonists of ARs are being studied in experimental models of left ventricle (LV) ischemia and dysfunction and systemic hypertension. Whether the development of selective and potent ligands for ARs could be an interesting treatment alternative in the context of PAH and RV failure remains speculative.

Roles of ARs in Proliferation of Pulmonary Vessel Cells
=======================================================

Repair of the pulmonary vessel cells in patients with PAH could be promoted by inhibition of the migration and/or proliferation of ECs, PASMCs, and/or fibroblasts. In this section, we describe recent findings for each AR subtype regarding their roles as targets to control PA wall remodeling and subsequent hypertrophy.

Several studies demonstrated the presence of ARs in lung in different species. For example, A~1~, A~2B~, and A~3~ receptors were detected in rat airway SMCs ([@B136]). In humans, levels of A~2B~ transcripts were the highest in bronchial SMCs; A~1~ and A~2A~ transcripts were detected as well, but A~3~ transcripts were below the detection limit ([@B218]). Immunohistochemical analyses of human lung parenchyma demonstrated expression of A~2A~ and A~3~ receptors in bronchiolar and alveolar epithelial cells, SMCs in bronchiolar and vessel walls, and ECs in the PAs ([@B200]). In contrast, A~2B~ receptor was expressed only in mast cells and macrophages, and A~1~ receptor was expressed only in a few alveolar macrophages ([@B200]). Differences in AR expression between rodents and humans might be due to the cell- and tissue-specific effects of hypoxia on their expression ([@B62]).

Few studies have addressed specific roles of the A~1~ receptor in the growth regulation of pulmonary vascular cells. This receptor subtype is down regulated in the pulmonary *vasa vasorum* ECs of calves with experimentally induced neonatal PH and in these cells the A~1~ receptor activation leads to actin cytoskeletal remodeling and a barrier formation in *vasa vasorum.* A~1~ activation in ECs could be targeted with the goal of reducing neovascularization and function of the *vasa vasorum*, indirectly contributing to the integrity of the pulmonary vasculature by preventing the triggering of inflammation ([@B198]). Nevertheless, A~1~ receptor could be only a vascular bed-specific target for PAH in advanced stages, by blocking *vasa vasorum* expansion in large pulmonary vessels. Although the knowledge of the influence of A~1~ receptor in animal model of PAH, this receptor is poorly expressed in human pulmonary vascular cells ([@B200]). Thus, it could be considered that A~1~ receptor may not be relevant to the progression of HAP, but it is important further evaluation to characterize specific functions of this adenosine receptor subtype in the small lung vasculature from PAH patients, since in some pathological conditions the adenosine receptors pattern might be changed.

A~2A~ is the most well-described AR subtype in the pulmonary circulation and in the context of PAH. Using an A~2A~ receptor knockout (KO) mouse model, [@B212] provided the first evidence of the critical contribution of A~2A~ to PAH development. At a postnatal age of 14--16 weeks, A~2A~ KO mice exhibited hemodynamic, histological, and ultrastructural characteristics suggestive of PAH. These changes included increases in RV systolic pressure, RV mass, and wall area and thickness, cellular proliferation in pulmonary resistance vessels, activation and hypertrophy of the PASMCs and ECs, and collagen deposition in the PA wall adventitia ([@B212]). The spontaneous PAH and altered PA remodeling were supported by the anatomical localization of A~2A~ in the vasculature, further demonstrating the functional activation of A~2A~ in ECs. These findings suggest that the effect of adenosine in PAH is likely mediated by the A~2A~ receptor in pulmonary vessels ([@B212]).

Recently, the same research group showed that A~2A~ KO mice exhibited key pathogenic characteristics of PAH, including muscularization of the pulmonary arterioles, PA remodeling, lumen narrowing, proliferation of pulmonary vascular ECs and SMCs, excessive hypertrophy of fibroblasts, and collagen deposition. A~2A~ KO mice overexpressed RhoA and ROCK mRNA and protein. As mentioned above, activation of RhoA/ROCK signaling may cause pulmonary vascular remodeling and development of PAH. Thus, this experimental study provides sufficient evidence for validation of the A~2A~ receptor as an anti-remodeling target in the pulmonary circulation ([@B176]). As such, this receptor may be a promising target for PAH therapy in the future ([@B8]). We agree with the authors on the need to confirm the specific downstream biochemical pathways that lead to inhibition of RhoA/ROCK signaling by A~2A~ receptor activation.

Salidroside, an active ingredient isolated from *Rhodiola rosea*, has multiple pharmacological activities, including anti-inflammatory, antioxidation, antistress, anticancer, and immune-enhancing effects. Salidroside effectively inhibited chronic hypoxia-induced PAH and PA remodeling by increasing A~2A~ expression and enhancing A~2A~-related mitochondria-dependent apoptosis. The authors suggested that it could be targeted for reducing vessel wall remodeling and hypertrophy in PAH ([@B93]).

New compounds of the class *N*-acylhydrazones were designed and synthetized to act as agonists of AR. The lead compound for these new derivatives was named LASSBio-294, which showed beneficial activity in rat model of MI ([@B27]; [@B31]) via activation of the A~2A~ receptor ([@B30]). LASSBio-294 has shown low efficacy in the rat model of PAH (data not published) which leads to explore the influence of adding the methyl group in the *N*-acylhydrazone function as a chemical strategy to optimize its pharmacological properties. Thus, among the new series of methylated *N*-acylhydrazone derivatives, LASSBio-1359 (EC~50~ = 6.6 ± 1.7 × 10^-6^ M) ([@B3]) and LASSBio-1386 (EC~50~ = 6.8 ± 0.6 × 10^-6^ M) ([@B2]), showed a more potent vasodilator effect in rat PAs than LASSBio-294 (EC~50~ = 7.0 ± 0.7 × 10^-2^ M). Those data reinforced the fact that the *N*-methyl group markedly changes the conformation of *N*-acylhydrazone function in the pulmonary vascular target. It was also previously described the importance of the presence of a small lipophilic group in substitution of the amide group of the *N*-acylhydrazone moiety to the increased cardiovascular effects ([@B178]).

Both compounds, LASSBio-1359 and LASSBio-1386, promoted PA vasodilation by the activation of the A~2A~ receptor, since their vascular effects were reduced by the selective antagonist of the A~2A~ receptor, ZM 241385 ([@B3], [@B2]). The binding assays for both substances confirmed their higher selectivity for the A~2A~ receptor subtype than for others (e.g., A~1~, A~2B~, and A~3~). LASSBio-1359 (10 μM), significantly inhibited the binding of agonist to the A~2A~ receptor (CGS21680) by an average of 78.6%, while for other receptors it did not surpass 30% inhibition ([@B3]). Furthermore, computational docking studies demonstrated how LASSBio-1359 and LASSBio-1386 might interact with the amino acid residues of the A~2A~ receptor crystal structure compared to the agonist CGS21680, supporting the fact that they were ligands of A~2A~ receptors ([@B3], [@B2]).

The involvement of the A~2A~ receptor in the regulation of cardiopulmonary physiology was investigated after administration of LASSBio-1359 and LASSBio-1386 in rats with monocrotaline-induced PAH ([@B3], [@B2]). Animals with monocrotaline-induced PAH, exhibited intense pulmonary microvessel remodeling and hypertrophy and when treated with LASSBio-1386 showed reductions of the proliferative changes in the pulmonary arterioles and pulmonary vascular remodeling. It was also observed a downregulation of the A~2A~ receptor in pulmonary tissue and RV tissue from rats with PAH ([@B2]). Another A~2A~ receptor ligand, LASSBio-1359, induced pulmonary vascular relaxation and promoted recovery of endothelial function in PA rings from rats with PAH. Monocrotaline-induced PAH produced fibromuscular hypertrophy and hyperplasia in the arteriole walls which in turn increased the RV systolic pressure and led to RV hypertrophy. However, daily oral treatment with the A~2A~ agonist abolished the increased RV overload and reduced vessel wall hypertrophy. Importantly, LASSBio-1359 exhibited satisfactory efficacy through long-term oral administration regimens in the cardiopulmonary system of rats with PAH, with no side effects in the systemic circulation, such as hypotension or a compensatory increase in heart rate ([@B3]).

Stimulation of the A~2A~ receptor effectively reduced neointimal layer formation in a murine model of carotid artery ligation ([@B134]). Collagen deposition and wall thickening were increased in the adventitial layer of PA walls from A~2A~ KO mice ([@B212]). Therefore, we speculate that in addition to its anti-inflammatory effects (addressed later in this review), A~2A~ exhibits anti-remodeling activity in the pulmonary vascular bed, through which it can reduce fibroblast migration and transdifferentiation into myofibroblasts during PAH pathogenesis. This possibility was supported by our study showing that the A~2A~ receptor agonist LASSBio-1359 reduced collagen deposition in the pulmonary arterioles of PAH rats ([@B3]). **Figure [1](#F1){ref-type="fig"}** shows an overview of the beneficial effects of A~2A~ receptor in the pathogenesis of PAH.

![Overview of pathophysiological mechanisms responsible for pulmonary arterial hypertension (PAH) development in lung pre-capillary arterioles. The beneficial effects of the adenosine A~2A~ receptor activation are highlighted in the green boxes. The events are sequentially numbered: (1) Triggers of PAH initially promote endothelial cells (EC) injury and dysfunction. The apoptosis-resistant ECs develop a hyperproliferative phenotype with a subsequent formation of obstructive plexiform lesions and this might be explained by (2) activation of transcription factors (TF) that promote a nuclear codification for an abnormal synthesis of growth factors (GF) and chemoattractants. (3) These GFs act activate receptors tyrosine kinase (RTK) in the ECs (autocrine signaling). (4) activation of RTK in ECs promotes gene transcription for the synthesis of (5) pro-proliferative proteins (e.g., RhoA/ROCK proteins). (6) ECs also release GFs that act in the pulmonary arterial smooth muscle cells (PASMC) triggering a paracrine signaling which is similar to what happens after activation of RTKs in ECs (steps 7 and 8) for the synthesis of pro-proliferative proteins. (9) Endothelial-derived chemoattractants and GFs also are responsible by fibroblasts migration and (10) collagen deposition (vessel wall fibrosis) with subsequent transdifferentiation into myofibroblasts. Other pathogenic characteristics of PAH are (11) increased endothelial production of vasoconstrictor molecules \[endothelin-1 (ET-1), angiotensin II (AngII) and serotonin (5-HT)\] and decreased release of vasodilators as nitric oxide (NO) and prostacyclin (PGI~2~), an event that is responsible by the (12) exacerbated vasoconstriction in the disease progression. (13) An inflammatory environment is formed by recruitment of several immunological cells, all of which releasing molecules as cytokines, chemokines, and interleukins that contribute to vascular remodeling and lung vessel injury through inflammation. A~2A~R, adenosine A~2A~ receptor; ROS, reactive oxygen species; RhoA/ROCK, pro-proliferative Rho kinases.](fphar-08-00858-g001){#F1}

Of the four ARs, A~2B~ has emerged as the receptor that regulates many of the adenosine-driven remodeling responses seen in chronic lung diseases ([@B104]). Although there have been no studies of the A~2B~ receptor in *in vivo* animal models or clinical PAH, there have been some studies of its roles in PH due to lung fibrosis or chronic obstructive pulmonary disease (COPD).

Pulmonary hypertension is a common and deadly complication of interstitial lung disease ([@B14]). Genetic removal of the A~2B~ receptor or treatment with its selective antagonist attenuated vascular remodeling in a mouse model of PH related to lung fibrosis. [@B105] proposed that A~2B~ receptor activation can promote the release of endothelin-1 and IL-6 from ECs and PASMCs, respectively, potentiating vessel wall remodeling and evolution to a PH phenotype. These authors later demonstrated an upregulation of the adenosine axis in lungs from patients with PH secondary to idiopathic pulmonary fibrosis, leading to enhanced accumulation of adenosine and expression of A~2B~. The authors stated that, under acute conditions, hyperactivation of the A~2B~ receptor by adenosine is protective and leads to lung tissue repair. In humans with lung fibrosis, however, sustained activation of the receptor is deleterious and contributes to development of pulmonary vascular remodeling and PH ([@B69]).

[@B200] reported that the A~2B~ receptor is expressed only in mast and macrophage immunologic cells of human lung. Recently, researchers found that conditional deletion of the A~2B~ receptor from myeloid cells was able to alter the phenotype of macrophages and dampen the development of fibrosis in a mouse model of lung injury-induced PH. The authors suggested a role for A~2B~-expressing myeloid cells as important regulators of fibrosis. These findings open the possibility of selectively blocking this AR subtype on macrophages as a novel therapeutic strategy for lung fibrosis and PH secondary to chronic lung diseases ([@B102]).

Patients with COPD frequently develop PAH, characterized by extensive remodeling of the pulmonary vasculature due to increased proliferation of PASMCs and ECs, muscularization of previously non-muscular arteries, increased vascular tone, and formation of complex vascular lesions. Alveolar hypoxia, inflammation, and emphysema in patients with COPD contribute to remodeling, vasoconstriction, and reduction of the vascular bed ([@B21]). Patients with both COPD and PH present remodeled vessels, characterized by increased smooth muscle and collagen deposition. Patient lung sections had elevated A~2B~ transcript levels, which were significantly correlated with increased PA pressures. Findings from this study suggest a role for A~2B~ receptor antagonism as treatment for PH secondary to COPD ([@B103]).

On the other hand, in an *in vitro* model of cultured PASMCs under hypoxic conditions, [@B161] showed that activation of the A~2B~ receptor induced antiproliferative effects. In another report, A~2B~ receptor stimulation counteracted PDGF-induced proliferation of human coronary SMCs through activating the exchange protein activated by cAMP ([@B131]). Antiproliferative effects mediated by A~2B~ receptors have been observed in studies of rat and human aortic and pre-glomerular SMCs and in human coronary SMCs ([@B43], [@B42], [@B44]; [@B97], [@B96]). In aortic-cultured SMCs, the proliferation-inducing transcription factor B-Myb elevated endogenous A~2B~ receptor mRNA and receptor activity levels, which, in turn, decreased cell proliferation ([@B185]). Accordingly, we assume that it would be of great importance to evaluate the specific roles of the A~2B~ receptor subtype and its agonists in both clinical and pre-clinical PAH experiments for further considerations about using this receptor as a target for the disease treatment. What would be an innovative strategy, antagonism or agonism of the A~2B~ receptor in PAH patients? This question might give a clue for the basic and clinical science about discovering any beneficial strategy concerning A~2B~ receptor for the treatment of PAH and its symptoms.

Regarding the specific roles of the A~3~ receptor in the proliferation of pulmonary vessel cells in the context of PAH, we did not find consistent studies to discuss in this review. Nevertheless, experiments performed in aortas from A~3~ receptor-deficient mice showed that this receptor has a role in increasing the proliferation of vascular SMCs ([@B100]). Another study demonstrated that A~3~ receptor activation in cultured human coronary SMCs was coupled to SMC proliferation via activation of phospholipase C and MAPK, with subsequent induction of the early growth response proteins EGR2 and EGR3 ([@B91]).

Roles of ARs in Inflammation
============================

There is divergent information regarding the A~1~ receptor in the inflammatory process. In several animal models of inflammation, A~1~ receptor mediated anti-inflammatory effect ([@B124]; [@B121]; [@B196]; [@B109]), however, A~1~ receptor is also implicated with altered vascular response and systemic inflammation in an allergic mouse model of asthma ([@B157]). Moreover, the block of A~1~ receptor attenuated endotoxin-induced lung injury in cats ([@B147]). Immune cells appear to exert activity mediated by activation of the A~1~ receptor because its activation may promote neutrophils adherence to endothelial cell and chemeotaxis ([@B13]). Neutrophils are cells recruited to tissue in response to pathogen (host defense) or some inflammatory disease ([@B13]). In early stage of inflammation the concentration of adenosine is low which may evoke neutrophil recruitment ([@B28]).

Evidences have suggested that anti-inflammatory effect via activation of A~2A~ receptor is a result of a positive stimulation of adenylate cyclase (AC) system with increased PKA levels and subsequently decrease NF-κB signaling through lower release of pro-inflammatory cytokines, such as TNF-α and IL-1β. Moreover, to decrease the release of interleukins and chemokines, the A~2A~ receptors activation inhibits events that occur during an immune response such as antigen presentation, adhesion and trafficking cellular, cell proliferation ([@B137]; [@B85]; [@B70]). A~2A~ receptors are expressed in CD4^+^ T lymphocytes cells which are inhibited in the heart after infarction of myocardium being the primarily target to A~2A~ agonist modulating a protective effect in heart ([@B215]). Furthermore, A~2A~ agonists reduce CD3^+^ T lymphocytes and neutrophils which could inhibit the cellular adhesion consequently no transmigration across endothelial cell occurs ([@B214]; [@B84]; [@B13]). Macrophage is a defense cell that can also migrate to inflammatory location and its regulation might be through adenosine receptor activation. There are two phenotypes of macrophage: phenotype 1 (M1) which is characterized by expression of several inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-12) and chemokines ensuring an inflammatory profile and phenotype 2 (M2) which controls inflammation and improves tissue healing. Stimulation of A~2A~ receptors might promote the change in the macrophage phenotype 1 to type 2 ([@B81]; [@B29]) promoting reduction of inflammation.

The A~2B~ receptors are preferentially coupled to stimulatory G protein ([@B64]), but also couple to Gq protein leading to the regulation of intracellular calcium levels ([@B55]; [@B126]). Activation of A~2B~ receptors might mediate mast cell function, increasing degranulation and stimulation of IL-8 secretion ([@B53], [@B54], [@B55]). In addition, the A~2B~ receptors activation increases IL-6 production by pulmonary fibroblasts, leading to the formation of myofibroblasts that deposit extracellular matrix ([@B83]). In contrast, A~2B~ receptors might modulate beneficial anti-inflammatory effect through the inhibition of neutrophils activity ([@B13]). Similarly to A~2A~ receptors, A~2B~ receptors when stimulated produce a change in the macrophage profile from phenotype 1 to phenotype 2.

The A~3~ receptors are widely expressed on immune cells and, upon binding their agonists, can activate phospholipase C and mediate inhibition of the PI3K/Akt and NF-kB signaling pathways to suppress production of TNF-α, IL-12, and IL-6 ([@B57], [@B56]; [@B202]; [@B120]; [@B50]).

RV Failure in PAH and Cardiac Profile of ARs
============================================

In an important review, [@B205] described the most relevant structural and functional changes to occur in the RV chamber subsequent to long-term pressure overload due to elevated PVR. The initial response of the right heart is myocardial remodeling and hypertrophy to compensate for the elevated postload, accompanied by progressive contractile dysfunction. Finally, the chamber dilates to allow compensatory preload and to maintain stroke volume despite the reduced systolic function. Patients may develop clinical evidence of RV failure, including elevated filling pressure, diastolic dysfunction, and reduced cardiac output. The LV develops diastolic dysfunction due to the increased size and pressure overload of the RV, such that PAH results in global heart failure ([@B205]). Maladaptive RV remodeling and subsequent hypertrophy might be accelerated by neurohormonal signaling, oxidative stress of cardiac cells, metabolic changes, and myocardial inflammation, which affect the cardiomyocytes, cardiac fibroblasts, and coronary vascular cells ([@B169]). Thus, we propose that a cardioprotective target should be beneficial by acting throughout all of the cardiac cells.

In the heart, adenosine might modulate the growth and death of cardiomyocytes, cardiac fibroblasts, ECs and SMCs, as well as affect the extracellular matrix ([@B85]). One important study evaluated the impact of chronic heart failure on the adenosine system and the effects of its stimulation on disease development in humans.

Patients with moderate heart failure who were treated with dipyridamole, an adenosine uptake inhibitor, exhibited reduced AR expression, increased adenosine levels, and symptom improvement ([@B9]). Hence, disturbances of the adenosine system might contribute to development of chronic heart failure.

Although preclinical and clinical studies have shown benefits of activating the A~1~ receptor in the context of LV dysfunction and failure ([@B48]; [@B86]; [@B124]; [@B154]; [@B24]; [@B38]), there is a lack of data regarding the effects of this receptor subtype in experimental models of PAH-induced RV impairment and global heart failure. We may discuss that the current unclear specific roles of this adenosine receptor subtype in the context of PAH should be the cause of researchers to consider it of low relevance.

Adenosine plays roles in the inflammatory process of LV heart failure. In cardiomyocytes from patients with LV heart failure, treatment with adenosine or the selective A~2~ receptor agonist DPMA decreased TNF-α expression levels by 40% or 87%, respectively ([@B206]). Activation of the A~2A~ receptor mediated the inflammatory process via activation of PKA, which, in turn, inhibited synthesis of proinflammatory molecules, such as TNF-α and IL-1β ([@B201]; [@B95]).

The A~2A~ receptor is expressed in mast cells ([@B129]), neutrophils ([@B65]), and CD4^+^ T cells ([@B115]). [@B210] showed that adult rat ventricular myocytes express adenosine A~2A~ receptor messenger RNA and through an immunoblotting technique, it was demonstrated that they express A~2A~ receptor protein ([@B108]). Although numerous *in vivo* studies of the A~2A~ receptor implicate its anti-inflammatory effects, some studies have suggested that its cardioprotective activities could be due, at least in part, to direct myocardial effects ([@B207]; [@B140]; [@B20]; [@B133]). Constitutive overexpression of the A~2A~ receptor in young mice with LV dysfunction was associated with increases in cardiac contractility, heart rate, and LV mass ([@B19]).

Cardiac overexpression of the A~2A~ receptor showed protective effects by attenuating fibrosis and improving cardiac function in a mouse model of heart failure ([@B79]). Another work showed that this receptor is expressed in cardiac fibroblasts, where it has an antifibrotic role ([@B173]).

As addressed earlier in this review, our laboratory has synthesized two new molecules, LASSBio-1359 and LASSBio-1386, from the lead compound LASSBio-294. Using *in silico* approaches, we identified a putative docking pose of this compound class at the A~2A~ receptor. *In vitro* assays of all three compounds indicate A~2A~ receptor agonist activity, although second messenger assays and full binding curves were not performed. The compounds exhibited vascular benefits and cardioprotective activities when administered chronically in rats with MI-induced LV heart failure ([@B27]; [@B31], [@B30]) or PAH-induced RV heart failure ([@B3], [@B2]). LASSBio-294 was chronically administered to normotensive and spontaneous hypertensive rats 4 weeks after MI. In addition to showing inotropic and lusitropic activities, this drug decreased cardiac remodeling, reduced cell infiltration, and improved Ca^2+^ influx into the sarcoplasmic reticulum in two different studies ([@B27]; [@B30]). In a third work, chronic administration of LASSBio-294 to rats 4 weeks after MI reduced exercise intolerance by recovering Ca^2+^ homeostasis in the skeletal muscle. LASSBio-294 prevented cellular infiltration into the skeletal muscle, similarly to what was described for cardiac muscle. We have proven that the beneficial effects of LASSBio-294 occur through its activation of the A~2A~ receptor ([@B30]) in the cardiac and skeletal muscles ([@B31]) and the subsequent increase of cAMP levels.

Given its salutary effects in animal models of left heart disease, we hypothesized that the A~2A~ receptor should show cardioprotective potential in both LV and RV tissues. We chronically administered our new adenosine A~2A~ agonists LASSBio-294 (data not published) LASSBio-1359 and LASSBio-1386 to rats with monocrotaline-induced RV failure ([@B3], [@B2]). Our new derivatives showed beneficial effects on the regulation of right heart physiology, as depicted by echocardiographic evaluations after long-term A~2A~ receptor activation (2 weeks of oral treatment with both substances) in monocrotaline-induced RV failure. Treatment of RV failure rats with LASSBio-1386 significantly improved their exercise capacity compared to control animals. Finally, we demonstrated, for the first time, that rats with RV failure had reduced A~2A~ receptor levels in RV tissue, which were correlated with reductions of SERCA2 content and Ca^2+^-ATPase activity. Activation of SERCA2 is one of the most important processes to regulate cardiomyocyte relaxation ([@B106]). SERCA induces Ca^2+^ uptake from the cytosol to the sarcoplasmic reticulum lumen, activating cell relaxation and promoting restock of Ca^2+^ for the next cardiac contraction. Elevated SERCA2 activity and density lead to an increased potential for the next cardiac cycle ([@B155]). These findings suggest the beneficial effects of A~2A~ receptor-mediated signaling on global cardiac function. Using echocardiography, we confirmed the impairment of systolic function in PAH rats ([@B2]). These data are consistent with previous reports showing an impaired pattern of this receptor in different experimental models of LV disease.

Additionally, we may discuss that the reduced expression of A~2A~ receptor in the cardiopulmonary tissues in rats with PAH-induced RV failure may be a consequence of the chronic state of the disease. Possibly, in earlier stage of PAH, the A~2A~ receptor expression could be unchanged or increased as a physiological compensatory mechanism. However, further studies are necessary to determine this receptor subtype levels during all stages of the disease in preclinical models. Despite the reduced expression of the A~2A~ receptor in the cardiopulmonary system on late stage of PAH, lower levels of the receptor were still detected and LASSBio-1359 and LASSBio-1386 could bind and activate these receptors, ameliorating PAH.

No study has investigated whether the A~2B~ receptor plays a role in RV function or in the pathophysiology of PAH-induced RV failure. However, this receptor is highly expressed in cardiac fibroblasts. Despite displaying antifibrotic potential in several *in vitro* studies, most *in vivo* animal models have described this receptor as being an inducer of cardiac remodeling and fibrosis. In their review, [@B203] proposed that some proinflammatory mechanism may underlie this profibrotic activity of the A~2B~ receptor. A~2B~ receptor promoted a moderate increase in cardiac contractility in *ex vivo* mouse hearts ([@B20]). A later study showed that A~2B~ receptor prevented mitochondrial oxidative stress by decreasing superoxide generation, but its effects were simultaneously potentiated by activation of the A~2A~ receptor. [@B211] concluded that the A~2A~ and A~2B~ receptors act together in the regulation of heart metabolism.

Given its high expression in mast cells, neutrophils, eosinophils, and other inflammatory cells, A~3~ receptor has been speculated as a potential target for the treatment of ischemic conditions, glaucoma, asthma, arthritis, cancer, and other inflammation-related disorders ([@B71]). Low-level expression of A~3~ receptor in the heart provided effective protection against ischemic injury without detectable adverse effects, whereas overexpression led to development of dilated cardiomyopathy. Expression of this receptor was below the limits of detection of radioligand binding or northern blot ([@B17]). Combined with the lack of works addressing the potential of A~3~ receptor in PAH and RV failure, we do not have enough arguments to assume that the synthesis of new ligands for this adenosine target could represent a suitable strategy to treat the disease in the future.

Conclusion
==========

Over the past 20 years, scientists in medicinal chemistry have generated agonists and antagonists with high affinity and high selectivity for human variants of each of the four ARs. Moreover, agonist and antagonist ligands containing positron-emitting radioisotopes have been developed to monitor the *in vivo* occupancy of ARs in humans ([@B144]; [@B22]). As such, the lack of selective ligands of ARs is not a limiting factor for research and drug development, as has been the case for some other G-protein coupled receptors. Furthermore, researchers continue their efforts to develop novel adenosine ligands with refined structure-activity relationships, improved *in vivo* biodistribution, and tissue selectivity, which are crucial to druggability ([@B144]; [@B22]). A bigger problem in this process has been the broad distribution of the ARs. A possible approach for achieving tissue selectivity could be the use of partial agonists that would predominantly act where there are a high number of so-called "spare" receptors ([@B22]), as we also commented earlier in this review.

Advances in our understanding of the pathogenetic role of adenosine in PAH may soon be translated into effective treatment options. There is a complex interplay among the different distribution patterns and/or affinities of the four AR subtypes in specific cell types at different stages of disease. As such, combinations of selective antagonist/agonists for the different AR subtypes will likely be required to obtain reasonable clinical efficacy. Alternatively, controlling the factors involved in driving adenosine concentrations in tissue may be important.

Regarding the roles of A~1~, A~2B~, and A~3~ adenosine receptor subtypes, with this review we are assuming the need of closely studying each one in specific pre-clinical models of PAH for further discussions on their use as targets to treat this deleterious cardiopulmonary disease in the clinical field.

Nevertheless, data discussed in this review indicate a role for the A~2A~ receptor in mediating beneficial effects, such as pulmonary vascular relaxation, reduction of pulmonary vessel and RV hypertrophy, amelioration of RV dysfunction, and exercise capacity, in rats with PAH. We have briefly described the importance of the adenosine system, specifically the A~2A~ receptor, as a new target for the treatment of PAH. Several factors remain to be explored. For example, global and local A~2A~ receptor function should be investigated in human PAH. The site of action of these drugs should be carefully determined through their administration to animals with cell-specific receptor deletions. Adenosine signaling and the effects of each drug over the specific disease course (e.g., acute and chronic stages of PAH and RV failure) should be carefully monitored in clinical studies. Finally, the possibility of combining direct A~2A~ receptor actions with drugs targeting other pathways and/or targets should be examined. Such explorations could uncover new therapeutic strategies, which are greatly needed for patients with PAH.
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